Kenley

Kenley is a clinical-stage biopharmaceutical company focused on developing innovative inhaled therapies for respiratory diseases, particularly Chronic Obstructive Pulmonary Disease (COPD) and asthma. The company was founded by the former leadership team of Pearl Therapeutics, which was acquired by AstraZeneca for its successful respiratory platform. Kenley utilizes a proprietary inhalation technology to optimize the delivery and efficacy of combination therapies, such as its lead program K-001. K-001 is a triple-combination treatment (ICS/LAMA/LABA) designed to provide superior lung function improvement compared to existing standards of care. Headquartered in Redwood City, California, Kenley aims to leverage its deep expertise in particle engineering and device design to address significant unmet needs in the global respiratory market.